2 patents currently held
29 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Jun 2031. from the record
Of the 29 now held by other companies, 23 name PHC Corporation as their current owner, and 6 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2031
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jun 2031 · High confidence
Also notable
Ends Aug 2041 · Medium confidence
Detection Method for Novel ROS1 Fusions
US 9,109,259
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2031.
Diagnosis Method for Bladder Cancer
US 12,742,781
Granted 2026. Too new for citation comparison; protection runs to 2041.
Formerly held, still cited
Notable
Ends Jun 2029 · High confidence
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2029.
now held by PHC Corporation
Also notable
Ends Jan 2031 · High confidence
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2031.
now held by PHC Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 18, 2027The maintenance fee for Detection Method for Novel ROS1 Fusions (US 9,109,259) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Diagnosis Method for Bladder Cancer | 1 in force | to Aug 2041 |
| Detection Method for Novel ROS1 Fusions | 1 in force | to Jun 2031 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,109,259 | Detection Method for Novel ROS1 Fusions In force · High confidence | In force | High confidence | |
| US 12,742,781 | Diagnosis Method for Bladder Cancer In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 29 patents in force now held by others · 19 patents ended · 3 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
8 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.